atherosclerosis regression

Related by string. * Atherosclerosis : carotid atherosclerosis . intracranial atherosclerosis . atherosclerosis hardening . subclinical atherosclerosis . coronary atherosclerosis . Atherosclerosis Risk / Regression . regressions : linear regression . multivariate logistic regression . multivariate regression analysis . regression analyzes . linear regression analysis * *

Related by context. Frequent words. (Click for all words.) 66 molecular biomarkers 62 Azedra 62 anti fibrotic 61 Mipomersen 61 ganetespib 61 liposomal formulation 60 enzastaurin 60 SERMs 60 calcitonin 60 SPC# [001] 60 INCB# [001] 60 biomarker 60 alagebrium 60 ataluren 60 Pervasis 60 xenograft models 60 TNFa 59 galectin 3 59 APOPTONE 59 LNPs 59 vorinostat 59 therapeutic regimens 59 vascular inflammation 59 clinically relevant 59 RBP4 59 CoFactor 59 Dasatinib 59 atherosclerotic disease 59 ZD# [001] 59 darapladib 58 deforolimus 58 remyelination 58 CA4P 58 GAP #B# 58 CR# vcMMAE 58 molecular profiling 58 noninvasive imaging 58 Cethromycin 58 neuroprotective properties 58 sipuleucel T 58 platelet reactivity 58 glucose homeostasis 58 prognostic marker 58 atherothrombosis 58 rNAPc2 58 murine model 58 biodistribution 58 GGF2 58 #ME# 58 OXi# 58 PSN# [002] 58 vascular disrupting agent 58 Factor VIIa 58 pertuzumab 58 Aurora kinase 58 P#X# 58 cardiometabolic risk 58 immunohistochemical 58 chemopreventive 58 Natalizumab 58 cardiovascular morbidity 58 MERLIN TIMI 58 CGEN # 58 forodesine 58 pharmacokinetic PK 57 tolvaptan 57 angiogenesis inhibitor 57 platelet activation 57 PEG SN# 57 lung fibrosis 57 otelixizumab 57 talactoferrin 57 cystatin C 57 stratify patients 57 regenerative therapies 57 QTinno 57 microRNA expression 57 cerebrospinal fluid CSF 57 antithrombotic 57 Carfilzomib 57 biomarkers 57 Celator 57 clusterin 57 therapeutically relevant 57 osteoblast 57 genetic polymorphisms 57 CCX# 57 pharmacodynamic effects 57 PK PD 57 diagnostic biomarkers 57 targeting CD# 57 atherogenic 57 therapeutic modality 57 VMAT2 57 gut microbiota 57 tanespimycin 57 surrogate markers 57 milatuzumab 57 phase IIa clinical 57 metreleptin 57 Phase 1b trial

Back to home page